ClinicalTrials.gg
CompletedNCT02491944Updated Oct 13, 2016Results posted

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

A Phase 1 interventional study of AZD9291 and [14C]AZD9291 in Oncology, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The Sponsor is developing the study drug, AZD9291, for the potential treatment of nonsmall cell lung cancer. Lung cancer has been the most common cancer in the world for several decades and represents 12.8% of all new cancer cases in 2008.

The purpose of this study is to see how much AZD9291 is taken up by the body when dosed by mouth (tablet) compared to when the study drug is dosed once by injection directly into the vein (intravenously). The dose given directly into the vein will be radiolabelled. This means that the test drug has a radioactive component which helps us to track where the drug is in the body. This allows us to detect the differences between the tablet and the intravenous dose.

The study will be performed in 12 healthy male subjects aged 18-65 years. On Day 1, subjects will be dosed with a single oral dose of 80 milligrams AZD9291 tablet followed by 100 micrograms [14C] AZD9291 dosed as an intravenous microdose beginning 5 hours and 45 minutes after the oral dose has been administered. Subjects will remain in the study centre until after the 120 hour post-dose blood sample is obtained and will return to the clinic for further visits on Day 8, 10, 15 and 22 for pharmacokinetic and safety assessments.

Read the detailed description

The study is a Phase I, open label, single dose, single centre study performed in 12 healthy male subjects aged 18 to 65 years, inclusive. This study will assess the absolute bioavailability of AZD9291 and evaluate the PK parameters following a single oral dose of AZD9291 and a radiolabelled IV microdose of AZD9291 in healthy male subjects. Oral AZD9291and [14C] AZD9291 intravenous solution are referred to as the investigational products in this study.

A screening visit (Visit 1) to assess the eligibility of the healthy male subjects will occur within 28 days of the administration of the investigational product. Screening assessments will include evaluation of opthalmological assessments, clinical chemistry, haematology, urinalysis, a physical examination, vital signs, 12-lead electrocardiograms (ECGs), medical and surgical history, screening for drugs of abuse, alcohol, hepatitis B and C, and HIV, and recording of concomitant medications and Adverse Events. Study related procedures will only be performed after signing of the Informed Consent Form.

The healthy male subjects will be admitted to the study centre the day before administration of the investigational product (Day 1; Visit 2). On Day 1 (Visit 2), subjects will be dosed with a single oral dose of 80 mg AZD9291 tablet followed by 100 μg [14C] AZD9291 dosed as an IV microdose beginning 5 hours and 45 minutes after the oral dose has been administered. The IV microdose will be infused over 15 minutes and the end of the infusion will be co incidental with median oral tmax (ie, estimated tmax is 6 hours).

The subjects will remain in the study centre until the 120 hour post dose PK blood sample is obtained. Ambulatory visits will occur on Days 8 (Visit 3), 10 (Visit 4), 15 (Visit 5) and 22 (Visit 6) for PK and safety assessments. A follow up visit (Visit 7) will occur 21 to 28 days after discharge (Days 27 - 34) from the study centre and will include routine safety assessments.

02

Conditions studied

  • Oncology

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 27 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed dated, written .
  2. Healthy male aged 18 to 65 yrs with suitable veins for blood sampling
  3. : 19 and 32 kg/m2 inclusive, weight at least 50 kg and no more than 100 kg, inclusive.
  4. At screening, calculated ≥50 mL/min using Cockcroft Gault formula.
  5. Willing to use defined methods of
  6. Willing and able to comply with study procedures, restrictions and requirements.
  7. Provision of informed consent for genetic research. Declining genetic research will not exclude subjects from other aspects of study.

Exclusion criteria

Exclusion Criteria:

  1. Involvement in planning and/or conduct of study.
  2. Subjects previously enrolled in this study.
  3. History of disease or disorder which, either puts subject at risk because of participation in study, or influences results or subject's ability to participate in study.
  4. History or presence of condition known to interfere with ADME of drugs.
  5. Any clinically significant abnormalities in physical examination, as judged by PI.
  6. Acute illness, surgical procedures, or trauma from within 2 wks before screening until first admin of product (IMP).
  7. Subjects who have received live or in 2 wks prior to IMP admin.
  8. Subjects with active or neoplastic disease in previous 12 mths.
  9. A suspected/manifested infection according to IATA Categories A and B.
  10. Positive screening tests for serum surface antigen, antibody, or .
  11. Any clinically important abnormalities in rhythm, conduction, or morphology of resting 12-lead , >470 ms.
  12. Known or suspected history of significant drug abuse.
  13. Positive screen for drugs of abuse or cotinine at screening or positive screen for alcohol, drugs of abuse, or cotinine on admission to centre prior to first admin of IMP.
  14. History of alcohol abuse or excessive intake of alcohol, defined as regular weekly intake of more than 21 units of alcohol in men
  15. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by PI, or history of hypersensitivity to AZD9291, its , or drugs with a similar chemical structure or class.
  16. Use of any prescribed or non-prescribed medication, including drugs during the 4 wks (or longer depending on the medication's half-life) prior to admin of AZD9291 is not permitted. Occasional use of paracetamol and adrenergic nasal spray for relief of nasal congestion is permitted at the discretion of the PI. Exceptions as agreed by PI and sponsor's medical monitor if do not interfere with aims of study.
  17. Use of drugs with enzyme inducing properties such as St John's Wort within 4 wks prior to IMP administration.
  18. Any intake of grapefruit, grapefruit juice, Seville oranges or products containing these fruit within 7 days of first admin of IMP.
  19. Blood donation within 1 mth of screening or any blood donation/blood loss greater than 500 mL during 3 mths prior to screening.
  20. Subjects who received another NCE or participated in any other clinical study (including methodology studies where no drugs were given) within 3 mths of first admin of IMP
  21. Judgment by PI that subject should not participate in study if subject is considered unlikely to comply with study procedures, restrictions, and requirements.
  22. Ongoing or planned inpatient surgery, dental procedure, or hospitalisation during study
  23. Radiation exposure exceeding 5 mSv in last 12 mths or 10 mSv in last 5 yrs.
  24. Admin of any amount of a [14C]-labelled compound within last 12 mths.
  25. Used of nicotine products (including cigarettes) within previous 3 mths.
  26. Judgment by PI that subject would not be able to understand or cooperate with requirements of study.
  27. Previous bone marrow transplant
  28. Blood transfusion within 120 days of genetic sample collection
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Bioavailability of AZD9291

    To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of \[14C\]AZD9291

    Drug: AZD9291 · Drug: [14C]AZD9291

Interventions

  • Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.

  • Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.

06

What researchers measure

Primary outcomes

  1. Absolute Oral Bioavailability

    Absolute bioavailability of AZD9291 will be calculated from area under the plasma concentration versus time curve (AUC) of the oral dose of AZD9291 / AUC of the IV dose of \[14C\]AZD9291 x IV dose/Oral dose x 100

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 5:45, 5:52, 6, 6:05, 6:10, 6:20, 6:25, 6:30, 7, 8, 9, 10, 12, 14, 16, 18, 24, 30, 48, 72, 120, 168, 216, 336 and 504 hours relative to the oral dose.

Secondary outcomes

  1. AUC for AZD9291 and it's Metabolites AZ5104 and AZ7550

    Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from zero to infinity for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  2. AUC(0-24) for AZD9291 and it's Metabolites AZ5104 and AZ7550

    Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 24 hours (AUC 0-24) for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  3. AUC(0-120) for AZD9291 and it's Metabolites AZ5104 and AZ7550

    Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 120 hours (AUC 0-120) for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  4. AUC(0-t) for AZD9291 and it's Metabolites AZ5104 and AZ7550

    Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to the last quantifiable concentration (AUC 0-t) for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  5. Cmax for AZD9291 and it's Metabolites AZ5104 and AZ7550

    PK profile of the oral dose of AZD9291 in terms of the maximum observed plasma concentration (Cmax) for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  6. Tmax for AZD9291 and it's Metabolites AZ5104 and AZ7550

    PK profile of the oral dose of AZD9291 in terms of the time to maximum observed plasma concentration (Tmax) for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  7. t1/2,λz for AZD9291 and it's Metabolites AZ5104 and AZ7550

    PK profile of the oral dose of AZD9291 in terms of the elimination half life (t1/2,λz) for AZD9291 and it's metabolites AZ5104 and AZ7550.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  8. CL/F for AZD9291

    PK profile of the oral dose of AZD9291 in terms of apparent total body clearance of drug from plasma after extravascular administration(CL/F) for AZD9291.

    Time frame: Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.

  9. AUC for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from zero to infinity for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  10. AUC(0-24) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 24 hours (AUC 0-24) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  11. AUC(0-120) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 120 hours (AUC 0-120) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  12. AUC(0-t) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to the last quantifiable concentration (AUC 0-t) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  13. Cmax for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of the maximum observed plasma concentration (Cmax) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  14. Tmax for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of the the time to maximum observed plasma concentration (Tmax) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  15. t1/2,λz for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of the elimination half life (t1/2,λz) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

  16. CL for [14C]AZD9291

    Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of total body clearance of drug from plasma after intravascular administration (CL) for \[14C\]AZD9291.

    Time frame: Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.

07

Results

Posted Oct 13, 2016

Participant flow

First subject enrolled: 10 July 2015; Last subject last visit: 26 August 2015. This study was conducted in a single study centre in the UK.

Participant flow — Overall Study
MilestoneAZD9291 and [14C]AZD9291
Started10
Completed10
Not completed0

Outcome measures

PrimaryAbsolute Oral Bioavailability

Absolute bioavailability of AZD9291 will be calculated from area under the plasma concentration versus time curve (AUC) of the oral dose of AZD9291 / AUC of the IV dose of \[14C\]AZD9291 x IV dose/Oral dose x 100

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 5:45, 5:52, 6, 6:05, 6:10, 6:20, 6:25, 6:30, 7, 8, 9, 10, 12, 14, 16, 18, 24, 30, 48, 72, 120, 168, 216, 336 and 504 hours relative to the oral dose.
Reported as:
Geometric mean · Percentage
Absolute Oral Bioavailability
PercentageAZD9291 and [14C]AZD9291
Absolute Oral Bioavailability69.75 (66.71 to 72.92)
SecondaryAUC for AZD9291 and it's Metabolites AZ5104 and AZ7550

Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from zero to infinity for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Geometric mean · nM*h
AUC for AZD9291 and it's Metabolites AZ5104 and AZ7550
nM*hAZD9291 and [14C]AZD9291
AZD92916791 ± 27.6
AZ5104694.5 ± 37.6
AZ7550602.5 ± 28.6
SecondaryAUC(0-24) for AZD9291 and it's Metabolites AZ5104 and AZ7550

Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 24 hours (AUC 0-24) for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Geometric mean · nM*h
AUC(0-24) for AZD9291 and it's Metabolites AZ5104 and AZ7550
nM*hAZD9291 and [14C]AZD9291
AZD92911963 ± 26.6
AZ5104113.7 ± 40.1
AZ755075.38 ± 33.8
SecondaryAUC(0-120) for AZD9291 and it's Metabolites AZ5104 and AZ7550

Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 120 hours (AUC 0-120) for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Geometric mean · nM*h
AUC(0-120) for AZD9291 and it's Metabolites AZ5104 and AZ7550
nM*hAZD9291 and [14C]AZD9291
AZD92915545 ± 25.3
AZ5104512.9 ± 37.2
AZ7550361.8 ± 28.8
SecondaryAUC(0-t) for AZD9291 and it's Metabolites AZ5104 and AZ7550

Pharmacokinetic (PK) profile of the oral dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to the last quantifiable concentration (AUC 0-t) for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Geometric mean · nM*h
AUC(0-t) for AZD9291 and it's Metabolites AZ5104 and AZ7550
nM*hAZD9291 and [14C]AZD9291
AZD92916770 ± 27.6
AZ5104684.4 ± 37.6
AZ7550591.2 ± 29.0
SecondaryCmax for AZD9291 and it's Metabolites AZ5104 and AZ7550

PK profile of the oral dose of AZD9291 in terms of the maximum observed plasma concentration (Cmax) for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Geometric mean · nM
Cmax for AZD9291 and it's Metabolites AZ5104 and AZ7550
nMAZD9291 and [14C]AZD9291
AZD9291118.0 ± 28.1
AZ51046.187 ± 38.0
AZ75504.302 ± 34.3
SecondaryTmax for AZD9291 and it's Metabolites AZ5104 and AZ7550

PK profile of the oral dose of AZD9291 in terms of the time to maximum observed plasma concentration (Tmax) for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Median · hours
Tmax for AZD9291 and it's Metabolites AZ5104 and AZ7550
hoursAZD9291 and [14C]AZD9291
AZD92917.01 ± 28.1
AZ510412.00 ± 38.0
AZ755011.03 ± 34.3
Secondaryt1/2,λz for AZD9291 and it's Metabolites AZ5104 and AZ7550

PK profile of the oral dose of AZD9291 in terms of the elimination half life (t1/2,λz) for AZD9291 and it's metabolites AZ5104 and AZ7550.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Mean · hours
t1/2,λz for AZD9291 and it's Metabolites AZ5104 and AZ7550
hoursAZD9291 and [14C]AZD9291
AZD929159.72 ± 4.257
AZ510452.59 ± 7.355
AZ755072.58 ± 11.86
SecondaryCL/F for AZD9291

PK profile of the oral dose of AZD9291 in terms of apparent total body clearance of drug from plasma after extravascular administration(CL/F) for AZD9291.

Time frame:
Samples taken at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 and 504 hours post-dose.
Reported as:
Mean · L/h
CL/F for AZD9291
L/hAZD9291 and [14C]AZD9291
CL/F for AZD929124.40 ± 6.979
SecondaryAUC for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from zero to infinity for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Geometric mean · nM*eq*h
AUC for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
nM*eq*hAZD9291 and [14C]AZD9291
[14C]AZD929112.12 ± 22.8
[14C]AZ51041.247 ± 26.8
[14C]AZ75501.177 ± 19.9
SecondaryAUC(0-24) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 24 hours (AUC 0-24) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Geometric mean · nM*eq*h
AUC(0-24) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
nM*eq*hAZD9291 and [14C]AZD9291
[14C]AZD92913.463 ± 21.6
[14C]AZ51040.1172 ± 36.1
[14C]AZ75500.08919 ± 28.5
SecondaryAUC(0-120) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to 120 hours (AUC 0-120) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Geometric mean · nM*eq*h
AUC(0-120) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
nM*eq*hAZD9291 and [14C]AZD9291
[14C]AZD92919.551 ± 22.1
[14C]AZ51040.7450 ± 34.4
[14C]AZ75500.5292 ± 28.9
SecondaryAUC(0-t) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of Area under the plasma concentration - time curve (AUC) from time zero to the last quantifiable concentration (AUC 0-t) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Geometric mean · nM*eq*h
AUC(0-t) for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
nM*eq*hAZD9291 and [14C]AZD9291
[14C]AZD929111.64 ± 25.7
[14C]AZ51040.8802 ± 44.2
[14C]AZ75500.6899 ± 38.1
SecondaryCmax for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of the maximum observed plasma concentration (Cmax) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Geometric mean · nM*eq
Cmax for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
nM*eqAZD9291 and [14C]AZD9291
[14C]AZD92910.5762 ± 68.6
[14C]AZ51040.008309 ± 36.1
[14C]AZ75500.005751 ± 34.2
SecondaryTmax for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of the the time to maximum observed plasma concentration (Tmax) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Median · hours
Tmax for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
hoursAZD9291 and [14C]AZD9291
[14C]AZD92910.25 ± 68.6
[14C]AZ510442.25 ± 36.1
[14C]AZ755033.27 ± 34.2
Secondaryt1/2,λz for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of the elimination half life (t1/2,λz) for \[14C\]AZD9291 and it's metabolites \[14C\]AZ5104 and \[14C\]AZ7550.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Mean · hours
t1/2,λz for [14C]AZD9291 and it's Metabolites [14C]AZ5104 and [14C]AZ7550
hoursAZD9291 and [14C]AZD9291
[14C]AZD929154.93 ± 9.032
[14C]AZ510468.35 ± 15.73
[14C]AZ755099.69 ± 29.33
SecondaryCL for [14C]AZD9291

Pharmacokinetic (PK) profile of the IV dose of AZD9291 in terms of total body clearance of drug from plasma after intravascular administration (CL) for \[14C\]AZD9291.

Time frame:
Samples taken pre-dose, during the infusion, immediately at the end of infusion and then at 5, 10, 20, 25 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 42, 66, 114, 162, 210, 330 and 498 hours after the end of the infusion.
Reported as:
Mean · L/h
CL for [14C]AZD9291
L/hAZD9291 and [14C]AZD9291
CL for [14C]AZD929116.84 ± 3.941

Adverse events

Collected over Adverse events were collected for 30 days starting from the dosing day. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9291 and [14C]AZD9291—0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventAZD9291 and [14C]AZD9291
CoughRespiratory, thoracic and mediastinal disorders1/10
DiarrhoeaGastrointestinal disorders1/10
Musculoskeletal painMusculoskeletal and connective tissue disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD9291 and [14C]AZD9291
Mean34.8 ± 13.29
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291 and [14C]AZD9291
Female0
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD9291 and [14C]AZD9291
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Research Site
    Nottingham, United Kingdom
09

References and documents

Publications

  • Vishwanathan K, So K, Thomas K, Bramley A, English S, Collier J. Absolute Bioavailability of Osimertinib in Healthy Adults. Clin Pharmacol Drug Dev. 2019 Feb;8(2):198-207. doi: 10.1002/cpdd.467. Epub 2018 Apr 23. PubMed 29683562 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2015
First posted
Jul 8, 2015
Start
Jul 2015
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Oct 13, 2016
Last update
Oct 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02491944
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 8, 2015
Start date
Jul 2015
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Oct 13, 2016
Last update
Oct 13, 2016

Study contacts

Joanne Collier, MBChB, FFPM, Dip Stats (OU)
principal investigator · Quotient Clinical Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion